The
cysteine proteases, cruzain and TbrCATL (rhodesain),
are therapeutic targets for Chagas disease and Human African Trypanosomiasis,
respectively. Among the known inhibitors for these proteases, we have
described N
4-benzyl-N
2-phenylquinazoline-2,4-diamine (compound 7 in the original publication, 1a in this study), as
a competitive cruzain inhibitor (K
i =
1.4 μM). Here, we describe the synthesis and biological evaluation
of 22 analogs of 1a, containing modifications in the
quinazoline core, and in the substituents in positions 2 and 4 of
this ring. The analogs demonstrate low micromolar inhibition of the
target proteases and cidal activity against Trypanosoma
cruzi with up to two log selectivity indices in counterscreens
with myoblasts. Fourteen compounds were active against Trypanosoma brucei at low to mid micromolar concentrations.
During the optimization of 1a, structure-based design
and prediction of physicochemical properties were employed to maintain
potency against the enzymes while removing colloidal aggregator characteristics
observed for some molecules in this series.